TY - JOUR
T1 - Antiviral treatment of covid-19
T2 - A clinical pharmacology narrative review
AU - Instiaty,
AU - Sri Darmayani, I. Gusti Agung Ayu Putu
AU - Marzuki, Jefman Efendi
AU - Angelia, Ferina
AU - William,
AU - Siane, Angelina
AU - Sary, Lela Dwi
AU - Yohanes, Lina
AU - Widyastuti, Reni
AU - Nova, Riki
AU - Simorangkir, Dewi Sharon
AU - Lonah,
AU - Safitri, Yolanda
AU - Aliska, Gestina
AU - Gayatri, Anggi
N1 - Publisher Copyright:
© 2020 Authors.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020. Repurposing old and relatively safe drugs becomes an advantageous option to obtain the urgently needed effective treatment. Repurposing chloroquine, hydroxychloroquine, oseltamivir, lopinavir/ritonavir, and favipiravir, and the use of investigational drug remdesivir for treatment of COVID-19, are reviewed from the clinical pharmacology perspective, particularly its efficacy and safety. Limited clinical studies of chloroquine, hydroxychloroquine, favipiravir, and remdesivir showed some efficacy in COVID-19 treatment with tolerable adverse effects. Potential serious adverse effect of chloroquine and hydroxychloroquine is cardiac arrhythmia. Oseltamivir has no documented activity against SARS-CoV-2, while lopinavir/ritonavir showed limited efficacy in COVID-19. Currently, there is no sufficient evidence to recommend any specific anti-COVID-19 treatment. The decision to use these drugs during the COVID-19 pandemic must be based on careful consideration of the potential benefits and risks to the patient.
AB - The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020. Repurposing old and relatively safe drugs becomes an advantageous option to obtain the urgently needed effective treatment. Repurposing chloroquine, hydroxychloroquine, oseltamivir, lopinavir/ritonavir, and favipiravir, and the use of investigational drug remdesivir for treatment of COVID-19, are reviewed from the clinical pharmacology perspective, particularly its efficacy and safety. Limited clinical studies of chloroquine, hydroxychloroquine, favipiravir, and remdesivir showed some efficacy in COVID-19 treatment with tolerable adverse effects. Potential serious adverse effect of chloroquine and hydroxychloroquine is cardiac arrhythmia. Oseltamivir has no documented activity against SARS-CoV-2, while lopinavir/ritonavir showed limited efficacy in COVID-19. Currently, there is no sufficient evidence to recommend any specific anti-COVID-19 treatment. The decision to use these drugs during the COVID-19 pandemic must be based on careful consideration of the potential benefits and risks to the patient.
KW - COVID-19
KW - Favipiravir
KW - Hydroxychloroquine
KW - Lopinavir
KW - Oseltamivir
KW - Remdesivir
UR - http://www.scopus.com/inward/record.url?scp=85094568032&partnerID=8YFLogxK
U2 - 10.13181/mji.rev.204652
DO - 10.13181/mji.rev.204652
M3 - Review article
AN - SCOPUS:85094568032
SN - 0853-1773
VL - 29
SP - 332
EP - 345
JO - Medical Journal of Indonesia
JF - Medical Journal of Indonesia
IS - 3
ER -